Mandibular osteonecrosis: clinical and imaging findings in a patient treated with denosumab
Keywords:
bisphosphonates, osteonecrosis of the jaws, denosumab, tooth extraction.Abstract
Introduction: The administration of bisphosphonates and antiangiogenic drugs in cancer patients is a usual therapeutic scheme in oncology. There are reports of osteonecrosis of the jaws in patients undergoing this treatment scheme, after performing an invasive dental procedure.
Objective: Show the dentist from the clinical and imaging characteristics of the pathology on the drugs for the treatment of cancer sensitivity to generate osteonecrosis of the jaws.
Case presentation: An 89-year-old male patient with prostate cancer treated with denosumab developed osteonecrosis of the lower jaw after tooth extraction. It is vitally important that the dentist identifies medications, risk factors and measures to minimize the risk of osteonecrosis of the jaws in sensitivy patients.
Downloads
References
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61(9):1115-7. DOI: 10.1016/s0278-2391(03)00720-1
Svejda B, Muschitz C, Gruber R, Brandtner C, Svejda C, Gasser RW, et al. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Wien Med Wochenschr. 2016;166(1-2):68-74. DOI:10.1007/s10354-016-0437-2
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-91. DOI:10.1359/jbmr.0707onj
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg; 2014 [Acceso: 30/07/2020];72(10):1938-56. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239114004637
Fassio A, Bertoldo F, Idolazzi L, Viapiana O, Rossini M, Gatti D. Drug-induced osteonecrosis of the jaw: the state of the art. Reumatismo; 2017 [Acceso: 30/07/2020];69(1):9. Disponible en: http://www.reumatismo.org/index.php/reuma/article/view/983
Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. J Clin Densitom; 2017 [Acceso: 30/07/2020];20(1):8-24. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1094695016301962
for the MASCC Bone Study Group, Nicolatou-Galitis O, Kouri M, Papadopoulou E, Vardas E, Galiti D, et al. Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review. Support Care Cancer; 2019 [Acceso: 30/07/2020];27(2):383-94. Disponible en: http://link.springer.com/10.1007/s00520-018-4501-x
Koth VS, Figueiredo MA, Salum FG, Cherubini K. Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. Dentomaxillofac Radiol; 2016 [Acceso: 30/07/2020];45(7):20160049. Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20160049
Lorenzo-Pouso AI, Pérez-Sayáns M, Chamorro-Petronacci C, Gándara-Vila P, López-Jornet P, Carballo J, et al. Association between periodontitis and medication-related osteonecrosis of the jaw: A systematic review and meta-analysis. J Oral Pathol Med. 2020;49(3):190-200.
Rodriguez-Lozano F, Oñate-Sanchez R. Treatment of osteonecrosis of the jaw related to bisphosphonates and other antiresorptive agents. Med Oral; 2016 [Acceso: 30/07/2020];0-0. Disponible en: http://www.medicinaoral.com/medoralfree01/aop/20980.pdf
Sartori P, Rajcovich G, Taborda N, Daza MC, Nally C. Osteonecrosis del maxilar inferior por bifosfonatos. Presentación de caso. Rev argent radiol. 16/12/2014;66.
Moreno-Sánchez M, Monje Gil F, González-García R, Manzano Solo de Zaldívar D. Bifosfonatos e implantes dentales, ¿son incompatibles? Revisión de la literatura. Rev Esp Cir Oral Maxilofac; 2016 [Acceso: 30/07/202038(3):128-35. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1130055814001294
Diaz-Reverand SA, Naval-Gíaz L, Muñoz-Guerra MF, Sastre-Pérez J, Rodríguez-Campo FJ, Gil-Diez JL, et al. Manejo de la osteonecrosis maxilar asociada al uso de medicamentos en virtud de su estadio clínico: análisis de 19 casos. Rev Esp Cir Oral Maxilofac; 2018 [Acceso: 30/07/2020];40(3):104-11. Disponible en: http://scielo.isciii.es/scielo.php?script=sci_abstract&pid=S1130-05582018000300104&lng=es&nrm=iso&tlng=es
Greenspan SL, Perera S, Ferchak MA, Nace DA, Resnick NM. Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women: A Randomized Clinical Trial. JAMA Intern Med; 2015 [Acceso: 30/07/2020];175(6):913. Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2015.0747
Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clin Belg; 2018 [Acceso: 30/07/2020];73(2):100-9. Disponible en: https://www.tandfonline.com/doi/full/10.1080/17843286.2017.1348001
Shibahara T. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Tohoku J Exp Med; 2019 [Acceso: 30/07/2020];247(2):75-86. Disponible en: https://www.jstage.jst.go.jp/article/tjem/247/2/247_75/_article
Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, et al. Five years of anti-resorptive activity after a single dose of zoledronate-Results from a randomized double-blind placebo-controlled trial. Bone; 2012 [Acceso: 30/07/2020];50(6):1389-93. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S875632821200734X
Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol; 2012 [Acceso: 30/07/2020];23(5):1341-7. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0923753419346952
Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol; 2012 [Acceso: 30/07/2020];48(9):817-21. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1368837512000978
Eleutherakis-Papaiakovou E, Bamias A. Antiresorptive treatment-associated ONJ. Eur J Cancer Care; 2017 [Acceso: 30/07/2020];26(6):e12787. Disponible en: http://doi.wiley.com/10.1111/ecc.12787
Yamashita J, McCauley LK. Antiresorptives and Osteonecrosis of the Jaw. J. Evid Based Dent Pract; 2012 [Acceso: 30/07/2020];12(3):233-47. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1532338212700465
Lo JC, O’Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, et al. Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure. J Oral Maxillofac Surg; 2010 [Acceso: 30/07/2020];68(2):243-53. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0278239109004418
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat; 2010 [Acceso: 30/07/2020];122(1):181-8. Disponible en: http://link.springer.com/10.1007/s10549-010-0866-3
Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, et al. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int; 2018 [Acceso: 30/07/2020];29(6):1407-17. Disponible en: http://link.springer.com/10.1007/s00198-018-4460-6
McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday. Am J Med; 2013 [Acceso: 30/07/2020];126(1):13-20. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0002934312005876
McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, et al. Opposite Bone Remodeling Effects of Teriparatide and Alendronate in Increasing Bone Mass. Arch Intern Med; 2005 [Acceso: 30/07/2020];165(15):1762. Disponible en: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/archinte.165.15.1762
Baba A, Ojiri H, Goto TK, Ikeda K, Yamauchi H, Ogino N, et al. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication). Jpn Dent Sci Rev; 2019 [Acceso: 30/07/2020];55(1):58-64. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S1882761618300929
Baba A, Goto TK, Ojiri H, Takagiwa M, Hiraga C, Okamura M, et al. CT Imaging Features of Antiresorptive agent-Related Osteonecrosis of the Jaw/ Medication-Related Osteonecrosis of the Jaws. Dentomaxillofac Radiol; 2018 [Acceso: 30/07/2020];20170323. Disponible en: http://www.birpublications.org/doi/10.1259/dmfr.20170323
Kakehashi H, Ando T, Minamizato T, Nakatani Y, Kawasaki T, Ikeda H, et al. Administration of teriparatide improves the symptoms of advanced bisphosphonate-related osteonecrosis of the jaw: preliminary findings. Int J Oral Maxillofac Surg; 2015 [Acceso: 30/07/2020];44(12):1558-64. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0901502715012011
Kagami H, Inoue M, Kobayashi A, Taguchi A, Li X, Yoshizawa M. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Oral Dis; 2018 [Acceso: 30/07/2020];24(1-2):52-6. Disponible en: http://doi.wiley.com/10.1111/odi.12783
Eguchi T, Kanai I, Basugi A, Miyata Y, Inoue M, Hamada Y. The assessment of surgical and non-surgical treatment of stage II medication-related osteonecrosis of the jaw. Med Oral; 2017 [Acceso: 30/07/2020];0-0. Disponible en: http://www.medicinaoral.com/medoralfree01/aop/22013.pdf
Published
How to Cite
Issue
Section
License
Authors retain all rights to their works, which they can reproduce and distribute as long as they cite the primary source of publication.
The Rev Cubana Estomatol is subject to the Creative Commons Attribution-Non-Commercial 4.0 International License (CC BY-NC 4.0) and follows the publication model of SciELO Publishing Schema (SciELO PS) for publication in XML format.
You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material.
The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
- You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation.
- No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.